Sidra Ghafoor
Psychiatry · Philadelphia, PANPI 1154765592
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $46,780 of the $56,320 with a category attached, or 83.1%. Otsuka America Pharmaceutical, Inc. accounts for 95.0% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $42,942, more than ten times the $988 reported in 2019. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $354.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$54K
- Alkermes, Inc.$877
- Neurocrine Biosciences, Inc.$745
- AbbVie$463
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$169
- Teva Pharmaceuticals USA, Inc.$157
- plus $382 from 6 others
What the payments were for
- Speaking & faculty fees$46,78083%
- Travel & lodging$4,9749%
- Food & beverage$4,5668%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 79 | $53,527 |
| Alkermes, Inc. | 5 | $877 |
| Neurocrine Biosciences, Inc. | 23 | $745 |
| AbbVie(2 entities) | 15 | $463 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $169 |
| Teva Pharmaceuticals USA, Inc. | 9 | $157 |
| Johnson & Johnson | 4 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $95 |
| Sunovion Pharmaceuticals Inc. | 5 | $81 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Lundbeck LLC | 1 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$52,016
- ABILIFY ASIMTUFII$51,893
- VIVITROL$800
- REXULTI$360
- INGREZZA$255
- VRAYLAR$250
How this compares
$56,320 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluvoxamine Maleate ErFluvoxamine Maleate | 12 | $3,384 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 27 | $2,384 |
| Modafinil | 12 | $980 |
| Divalproex Sodium | 18 | $346 |
| Quetiapine Fumarate | 35 | $261 |
| Bupropion XlBupropion Hcl | 22 | $229 |
| Fluoxetine Hcl | 18 | $181 |
| Olanzapine | 12 | $137 |
| Clonazepam | 20 | $132 |
| Mirtazapine | 17 | $111 |
| Aripiprazole | 16 | $108 |
| Gabapentin | 16 | $89 |
| Sertraline Hcl | 11 | $73 |
| Alprazolam | 13 | $27 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Philadelphia
- Daniel WeintraubPhiladelphia$647K
- Michael ThasePhiladelphia$396K
- Freddy AliPhiladelphia$107K
- Richard JaffePhiladelphia$101K
- Ramesh EluriPhiladelphia$85K
- John LaurielloPhiladelphia$62K
- Maria OquendoPhiladelphia$50K
- David OslinPhiladelphia$30K
- Bianca PrevidiPhiladelphia$28K
- Steven ArnoldPhiladelphia$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.